Holen Sie sich die Stockscreener-App
65.14
2.57%
1.63
Handel nachbörslich:
65.14
Schlusskurs vom Vortag:
$63.51
Offen:
$64
24-Stunden-Volumen:
11,872
Relative Volume:
0.24
Marktkapitalisierung:
$2.07B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.61M
KGV:
-55.48
EPS:
-1.1742
Netto-Cashflow:
-
1W Leistung:
+0.98%
1M Leistung:
-6.66%
6M Leistung:
+8.93%
1J Leistung:
+34.56%
1-Tages-Spanne:
$64.00
$65.71
1-Wochen-Bereich:
$62.18
$66.15
52-Wochen-Spanne:
$43.70
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
Firmenname
Belite Bio Inc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BLTE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
65.14 | 2.15B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Maxim Group | Buy |
| 2023-07-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Eingeleitet | SVB Securities | Outperform |
| 2022-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-01 | Eingeleitet | The Benchmark Company | Buy |
Belite Bio Inc Adr Aktie (BLTE) Neueste Nachrichten
Fed Meeting: Can Belite Bio Inc Depositary Receipt maintain its current growth rate2025 Stock Rankings & Fast Entry High Yield Tips - khodrobank.com
Developing predictive dashboards with Belite Bio Inc Depositary Receipt data2025 Big Picture & Long-Term Growth Stock Strategies - Newser
Does Belite Bio Inc Depositary Receipt fit your quant trading model2025 Technical Patterns & Long-Term Safe Investment Plans - Newser
Belite Bio’s Earnings Call: Progress Amid Challenges - MSN
Is Belite Bio Inc Depositary Receipt showing signs of accumulationQuarterly Earnings Report & Entry and Exit Point Strategies - Newser
Clinical-Stage Biotech Belite Bio Secures Speaking Slots at Three Premier Healthcare Conferences - Stock Titan
Multi factor analysis applied to Belite Bio Inc Depositary ReceiptQuarterly Performance Summary & AI Driven Price Forecasts - Newser
Is Belite Bio Inc Depositary Receipt stock bottoming out2025 Price Momentum & Fast Exit Strategy with Risk Control - Newser
Promising Clinical Trials and Strong Financial Position Reinforce Buy Rating for Belite Bio - TipRanks
Q3 EPS Estimates for Belite Bio Lowered by Leerink Partnrs - Defense World
Belite Bio FY2029 EPS Forecast Reduced by Leerink Partnrs - Defense World
Belite Bio’s Tinlarebant: A Promising Investment with Breakthrough Potential for Stargardt Disease - TipRanks
Benchmark Co. Reiterates Buy Rating on Belite Bio, Sets $80 Price Target - AInvest
Benchmark reiterates Buy rating on Belite Bio stock, maintains $80 price target - Investing.com Nigeria
Benchmark reiterates Buy rating on Belite Bio stock, maintains $80 price target By Investing.com - Investing.com South Africa
Promising Clinical Trials and Regulatory Advancements Support Buy Rating for Belite Bio, Inc. - TipRanks
Belite Bio targets NDA submission for Tinlarebant in first half of 2026 amid strong cash runway and Phase III progress - MSN
Belite Bio Advances Retinal Disease Treatments Amid Financial Growth - TipRanks
Belite Bio's Tinlarebant: A Groundbreaking Therapy on the Cusp of Approval in Stargardt Disease and Geographic Atrophy - AInvest
Belite Bio Aims for NDA Submission by H1 2026 with Robust Cash Runway and Advancing Phase III Trials - AInvest
Belite Bio Q2 2025 presentation: expenses rise as clinical trials advance - Investing.com Canada
Earnings call transcript: Belite Bio Q2 2025 beats EPS expectations despite losses - Investing.com Nigeria
Belite Bio Q2 2025 Earnings Call Transcript - MarketBeat
Belite Bio Shares Drop Despite Clinical Milestones - TipRanks
Belite Bio reports Q2 EPS (50c), consensus (42c) - TipRanks
Belite Bio Announces Q2 2025 Financial Results and Key Clinical Milestones - TipRanks
Why Belite Bio's Widening Losses Signal a High-Probability Path to Market Leadership in Retinal Therapies - AInvest
Belite Bio's Tinlarebant: A First-in-Class Therapeutic Candidate with Dual-Indication Potential in High-Value Retinal Diseases - AInvest
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - The Globe and Mail
FDA Grants Breakthrough Status to Belite Bio's First-Ever Stargardt Disease Treatment as Phase 3 Trials Advance - Stock Titan
Belite Bio, Inc. ADR: Stock Movement Explained - TipRanks
Belite Bio Announces $15 Million Direct Offering - TipRanks
Belite Bio raises $15 million in registered direct offering - Investing.com
Belite Bio Raises $15M in Strategic Financing with Potential for Additional $15M from Warrants - Stock Titan
Belite Bio Experts Join Pivotal Retinal Disease Panel at Major Ophthalmology Conference - Stock Titan
New Strong Sell Stocks for August 4th - sharewise.com
Belite Bio Announces Q2 Earnings Call: Latest Updates on Novel Retinal Disease Therapeutics Pipeline - Stock Titan
New Strong Sell Stocks for July 22nd - The Globe and Mail
Belite Bio (BLTE) Expected to Announce Earnings on Friday - Defense World
Leading vs lagging indicators on Belite Bio Inc Depositary Receipt performanceDay Trading Plan with Entry Risk Management - Newser
A Look At The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE) - uk.finance.yahoo.com
Belite Bio Executives Share Latest Retinal Disease Breakthroughs at BTIG Biotech Conference - Stock Titan
New Strong Sell Stocks For July 22nd - Barchart.com
What analysts say about Belite Bio Inc Depositary Receipt stockConsistent wealth multiplication - jammulinksnews.com
Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant - Eyes On Eyecare
Stargardt Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Q2 EPS Estimates for Belite Bio Decreased by Leerink Partnrs - Defense World
Ouster Announces Date for Second Quarter 2025 Earnings Call - The Globe and Mail
Belite Bio completes enrollment in global phase 3 PHOENIX trial for geographic atrophy - Ophthalmology Times
Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential - TipRanks
Finanzdaten der Belite Bio Inc Adr-Aktie (BLTE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):